Chemoprevention of Oral Premalignant Lesions

Susan T. Mayne, Brenda Cartmel, Douglas E. Morse

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Oral precancerous lesions have been relatively well studied in the chemoprevention research. Oral precancerous lesions are used as intermediate end point biological markers to help screen potential chemopreventive agents that might have utility in the prevention of oral and pharyngeal cancers. Chemoprevention of these lesions has direct clinical relevance and can also be used to screen agents that may have efficacy in the prevention of oral, pharyngeal, or other cancers. This chapter introduces various types of oral premalignant lesions, discusses design and interpretation issues of relevance to chemoprevention trials in this clinical setting, and reviews the results of chemoprevention trials of oral premalignancy. Several agents that have been evaluated for chemopreventive efficacy in oral precancerous lesions include various retinoids, β-carotene, the algae Spirulina fusiformis, vitamin E, selenium, tea, protease inhibitors, and bleomycin. Some of these agents have established efficacy in terms of regressing oral precancerous lesions, demonstrating proof of the principle behind chemoprevention of oral premalignancy. However, these same agents have limitations to their widespread use for this purpose. The chapter concludes with a discussion of the validity of oral precancerous lesions in predicting the efficacy of agents for oral-cancer prevention and discusses the challenges that lie ahead with regard to identifying suitable agents with clear evidence of efficacy but without significant toxicity.

Original languageEnglish (US)
Title of host publicationHead and Neck Cancer: Emerging Perspectives
PublisherElsevier Inc.
Pages261-269
Number of pages9
ISBN (Print)9780122399909
DOIs
StatePublished - 2003

Fingerprint

Chemoprevention
Mouth Neoplasms
Pharyngeal Neoplasms
Spirulina
Bleomycin
Retinoids
Tea
Carotenoids
Selenium
Protease Inhibitors
Vitamin E
Biomarkers
Algae
Clinical Trials
Toxicity
Research
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mayne, S. T., Cartmel, B., & Morse, D. E. (2003). Chemoprevention of Oral Premalignant Lesions. In Head and Neck Cancer: Emerging Perspectives (pp. 261-269). Elsevier Inc.. https://doi.org/10.1016/B978-012239990-9/50019-9

Chemoprevention of Oral Premalignant Lesions. / Mayne, Susan T.; Cartmel, Brenda; Morse, Douglas E.

Head and Neck Cancer: Emerging Perspectives. Elsevier Inc., 2003. p. 261-269.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mayne, ST, Cartmel, B & Morse, DE 2003, Chemoprevention of Oral Premalignant Lesions. in Head and Neck Cancer: Emerging Perspectives. Elsevier Inc., pp. 261-269. https://doi.org/10.1016/B978-012239990-9/50019-9
Mayne ST, Cartmel B, Morse DE. Chemoprevention of Oral Premalignant Lesions. In Head and Neck Cancer: Emerging Perspectives. Elsevier Inc. 2003. p. 261-269 https://doi.org/10.1016/B978-012239990-9/50019-9
Mayne, Susan T. ; Cartmel, Brenda ; Morse, Douglas E. / Chemoprevention of Oral Premalignant Lesions. Head and Neck Cancer: Emerging Perspectives. Elsevier Inc., 2003. pp. 261-269
@inbook{4e319e29c75644baa19e038fd184eec7,
title = "Chemoprevention of Oral Premalignant Lesions",
abstract = "Oral precancerous lesions have been relatively well studied in the chemoprevention research. Oral precancerous lesions are used as intermediate end point biological markers to help screen potential chemopreventive agents that might have utility in the prevention of oral and pharyngeal cancers. Chemoprevention of these lesions has direct clinical relevance and can also be used to screen agents that may have efficacy in the prevention of oral, pharyngeal, or other cancers. This chapter introduces various types of oral premalignant lesions, discusses design and interpretation issues of relevance to chemoprevention trials in this clinical setting, and reviews the results of chemoprevention trials of oral premalignancy. Several agents that have been evaluated for chemopreventive efficacy in oral precancerous lesions include various retinoids, β-carotene, the algae Spirulina fusiformis, vitamin E, selenium, tea, protease inhibitors, and bleomycin. Some of these agents have established efficacy in terms of regressing oral precancerous lesions, demonstrating proof of the principle behind chemoprevention of oral premalignancy. However, these same agents have limitations to their widespread use for this purpose. The chapter concludes with a discussion of the validity of oral precancerous lesions in predicting the efficacy of agents for oral-cancer prevention and discusses the challenges that lie ahead with regard to identifying suitable agents with clear evidence of efficacy but without significant toxicity.",
author = "Mayne, {Susan T.} and Brenda Cartmel and Morse, {Douglas E.}",
year = "2003",
doi = "10.1016/B978-012239990-9/50019-9",
language = "English (US)",
isbn = "9780122399909",
pages = "261--269",
booktitle = "Head and Neck Cancer: Emerging Perspectives",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Chemoprevention of Oral Premalignant Lesions

AU - Mayne, Susan T.

AU - Cartmel, Brenda

AU - Morse, Douglas E.

PY - 2003

Y1 - 2003

N2 - Oral precancerous lesions have been relatively well studied in the chemoprevention research. Oral precancerous lesions are used as intermediate end point biological markers to help screen potential chemopreventive agents that might have utility in the prevention of oral and pharyngeal cancers. Chemoprevention of these lesions has direct clinical relevance and can also be used to screen agents that may have efficacy in the prevention of oral, pharyngeal, or other cancers. This chapter introduces various types of oral premalignant lesions, discusses design and interpretation issues of relevance to chemoprevention trials in this clinical setting, and reviews the results of chemoprevention trials of oral premalignancy. Several agents that have been evaluated for chemopreventive efficacy in oral precancerous lesions include various retinoids, β-carotene, the algae Spirulina fusiformis, vitamin E, selenium, tea, protease inhibitors, and bleomycin. Some of these agents have established efficacy in terms of regressing oral precancerous lesions, demonstrating proof of the principle behind chemoprevention of oral premalignancy. However, these same agents have limitations to their widespread use for this purpose. The chapter concludes with a discussion of the validity of oral precancerous lesions in predicting the efficacy of agents for oral-cancer prevention and discusses the challenges that lie ahead with regard to identifying suitable agents with clear evidence of efficacy but without significant toxicity.

AB - Oral precancerous lesions have been relatively well studied in the chemoprevention research. Oral precancerous lesions are used as intermediate end point biological markers to help screen potential chemopreventive agents that might have utility in the prevention of oral and pharyngeal cancers. Chemoprevention of these lesions has direct clinical relevance and can also be used to screen agents that may have efficacy in the prevention of oral, pharyngeal, or other cancers. This chapter introduces various types of oral premalignant lesions, discusses design and interpretation issues of relevance to chemoprevention trials in this clinical setting, and reviews the results of chemoprevention trials of oral premalignancy. Several agents that have been evaluated for chemopreventive efficacy in oral precancerous lesions include various retinoids, β-carotene, the algae Spirulina fusiformis, vitamin E, selenium, tea, protease inhibitors, and bleomycin. Some of these agents have established efficacy in terms of regressing oral precancerous lesions, demonstrating proof of the principle behind chemoprevention of oral premalignancy. However, these same agents have limitations to their widespread use for this purpose. The chapter concludes with a discussion of the validity of oral precancerous lesions in predicting the efficacy of agents for oral-cancer prevention and discusses the challenges that lie ahead with regard to identifying suitable agents with clear evidence of efficacy but without significant toxicity.

UR - http://www.scopus.com/inward/record.url?scp=84864223607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864223607&partnerID=8YFLogxK

U2 - 10.1016/B978-012239990-9/50019-9

DO - 10.1016/B978-012239990-9/50019-9

M3 - Chapter

SN - 9780122399909

SP - 261

EP - 269

BT - Head and Neck Cancer: Emerging Perspectives

PB - Elsevier Inc.

ER -